| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 57.2 | 58.3 | 48.0 |
| Other income | 0.2 | 0.3 | 0.3 |
| Total income | 57.4 | 58.6 | 48.3 |
| Profit before exceptional items & tax | 7.8 | 8.8 | 1.8 |
| Profit before tax | 7.8 | 8.8 | 1.8 |
| Net profit | 5.7 | 6.6 | 1.3 |
| Operating margin | 13.6% | 15.0% | 3.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +338.50% |
|---|---|
| Net profit, quarter on quarter | -13.60% |
| Revenue, year on year | +19.20% |
NSE results filing, NSE: SAAKSHI. Figures extracted from the filing.
Saakshi Medtech & Panels Ltd: key numbers
- Share price
- ₹365.70
- Market cap
- ₹719.2 Cr
- Revenue (annual)
- ₹115.5 Cr
- Net profit (annual)
- ₹12.29 Cr
- P/E (TTM)
- 58.5×Sector 53.6×
- Promoter holding
- 74.82%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saakshi Medtech & Panels Ltd
All →Saakshi Medtech & Panels Management Change
Saakshi Medtech and Panels Limited issued a revised disclosure regarding the appointment of Mr. Nandkumar Vasant Dhekne as Independent Director and Mr. Ravi Madhav Vartak as Whole-time Director.
Saakshi Medtech & Panels Capital Structure Change
Saakshi Medtech and Panels Limited received NSE's in-principle approval to list 2,010,259 equity shares of ₹10 each issued via preferential allotment.
Saakshi Medtech & Panels Annual General Meeting
Saakshi Medtech and Panels Limited has scheduled its 17th Annual General Meeting for September 30, 2026. Shareholders will consider financial statements and director appointments.
Saakshi Medtech & Panels Board Meeting Outcome
Saakshi Medtech and Panels Limited announced the re-appointment of Mr. Aniket Latkar as Chairman and Managing Director for a five-year term, effective June 8, 2026.
- Execution
- 5 years